Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026GlobeNewsWire · Oct 18, 2026
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination PotentialSeeking Alpha · Oct 7, 2026
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockGlobeNewsWire · Oct 5, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common StockGlobeNewsWire · Oct 5, 2026
Spyre (NASDAQ: SYRE) legal chief trims stake in planned share saleDefense World · Oct 4, 2026
Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewsWire · Oct 2, 2026Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.76 | -$0.36 | Beat |
| May 5, 2026 | -$0.66 | -$0.74 | Miss |
| Feb 19, 2026 | -$0.66 | -$0.70 | Miss |
| Nov 4, 2025 | -$0.76 | -$0.15 | Beat |
| Aug 5, 2025 | -$0.73 | -$0.49 | Beat |
| May 8, 2025 | -$0.84 | -$0.74 | Beat |